Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors from the central nervous procedure, conolidine modulates alternate molecular targets. A Science Advancements examine located that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://carlosu083ygo0.blogsuperapp.com/profile